《異動股》中國鼎益豐(00612.HK)續彈1.1倍曾重越2元交投活躍
上月24日起委任馬小秋為公司新主席的中國鼎益豐(00612.HK)價量連續第二天呈異動,承昨天股價彈28%勢,今天最多再急彈1.2倍至2.02元遇壓,現造1.91元,續彈1.1倍,成交續增至7,816萬股,為近期最多,涉資1.155億元。
證監會上月22日曾公布,決定將就中國鼎益豐涉嫌市場操控活動,對多名人士展開法律程序,並決定撤銷公司於去年3月8日作出有關暫停股份交易指示。另外,公司1月23日公布,隋廣義辭任公司主席職位。該股1月23日復牌股價由停牌前23.1元,暴瀉91%曾低見1.6元創近兩年半低。(sz/t)~
阿思達克財經新聞
網址: www.aastocks.com
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.